fucking livid
Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in animal models, and the trial results were eagerly awaited as one of the most promising treatments in years. It did not work. “Crenezumab did not slow or prevent cognitive decline” in people with a predisposition toward Alzheimer’s.
Last year, the Food and Drug Administration (FDA) narrowly approved the use of Aduhelm, a new drug from Biogen that the company has priced so highly that it’s expected to drive up the price of Medicare for everyone in America, even those who never need this drug. Aduhelm was the first drug to be approved that fights the accumulation of those “amyloid plaques” in the brain. What makes the approval of the $56,000-a-dose drug so controversial is that while it does decrease plaques, it doesn’t actually slow Alzheimer’s. In fact, clinical trials were suspended in 2019 after the treatment showed “no clinical benefits.” (Which did not keep Biogen from seeking the drug’s approval or pricing it astronomically.)
Over the last two decades, Alzheimer’s drugs have been notable mostly for having a 99% failure rate in human trials. It’s not unusual for drugs that are effective in vitro and in animal models to turn out to be less than successful when used in humans, but Alzheimer’s has a record that makes the batting average in other areas look like Hall of Fame material.
And now we have a good idea of why. Because it looks like the original paper that established the amyloid plaque model as the foundation of Alzheimer’s research over the last 16 years might not just be wrong, but a deliberate fraud.
thanks for the text extraction, i was on my phone <3
Jesus christ
fuleao liked this
whisttypbuckgyl liked this
konmekaka liked this
condemnedcas liked this
daypoupindti liked this
rappacheeks reblogged this from beatrice-otter
most-definitively-a-human reblogged this from theorderofthetriad
most-definitively-a-human liked this dancingcacti reblogged this from chalkrevelations
siderewinders reblogged this from siderewinders
gothellewoods liked this
queerwizarrds reblogged this from will-shut-up-4-wifi
riverdaleseason5 liked this intenxty reblogged this from ejacutastic
ease-out-the-clutch reblogged this from msbehavoyeur
msbehavoyeur reblogged this from mosertone vandisa liked this
sighofregret liked this
theatheistgirl liked this
scp-bumblebee reblogged this from themboots
darkinternalthoughts liked this lethargy-lifestyle liked this
shortylaw liked this
themboots reblogged this from mosertone
jupit7r reblogged this from mosertone smackmyglitchup liked this
left-the-porch reblogged this from mosertone
left-the-porch liked this
tioloup liked this chapelofthechimes reblogged this from niceofthenine
clarritea liked this zombiebro liked this
weird-one-23 reblogged this from weird-one-23
comradenidhogg reblogged this from komsomolka
deodatasslawson reblogged this from komsomolka
deodatasslawson liked this
madain-sari reblogged this from eastofthemoon
badwolfonthebay reblogged this from danteswornofkischou
enchantedblackforest reblogged this from gettothestabbing
ronjawood-thoughts reblogged this from gettothestabbing saxifraga-x-urbium posted this
Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting...
- Show more notes
